| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Laboratory of Biosystems and Cancer, National Cancer Institute, Bethesda, Maryland; 2 Walter Reed Army Medical Center, Washington, District of Columbia; and 3 Department of Obstetrics and Gynecology/Division of Gynecologic Oncology, Duke University, Durham, North Carolina
Requests for reprints: John I. Risinger, Laboratory of Biosystems and Cancer, NIH/National Cancer Institute, Room 5046, Building 37, 9000 Rockville Pike, MSC 4264, Bethesda, MD. Phone: 301-594-8503; E-mail: risingej{at}mail.nih.gov.
Microsatellite instability (MSI) is a molecular phenotype present in 
25% of endometrial cancers. We examined the global gene expression profiles of early-stage endometrioid endometrial cancers with and without the MSI phenotype to test the hypothesis that MSI phenotype may determine a unique molecular signature among otherwise similar cancers. Unsupervised principal component analysis of the expression data from these cases indicated two distinct groupings of cancers based on MSI phenotype. A relatively small number of array features (392) at high statistical value (P < 0.001) were identified that drive the instability signature in these cancers; 109 of these transcripts differed by at least 2-fold. These data identify distinct gene expression profiles for MSI and microsatellite stable (MSS) cancers, which suggest that cancers with MSI develop in part by different mechanisms from their similar stable counterparts. In particular, we found evidence that two members of the secreted frizzled related protein family (SFRP1 and SFRP4) were more frequently down-regulated in MSI cancers as compared with MSS cancers. Down-regulation was accompanied by promoter hypermethylation for SFRP1. SFRP1 was hypermethylated in 8 of 12 MSI cancers whereas only 3 of 16 MSS cancers were methylated. The WNT target fibroblast growth factor 18 was found to be up-regulated in MSI cancers. These data classify histologically similar endometrioid endometrial cancers into two distinct groupings with implications affecting therapy and prevention.
This article has been cited by other articles:
|
|
 |
|
  K. S. Carmon and D. S. Loose Secreted Frizzled-Related Protein 4 Regulates Two Wnt7a Signaling Pathways and Inhibits Proliferation in Endometrial Cancer Cells Mol. Cancer Res., June 1, 2008; 6(6): 1017 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Zighelboim, P. J. Goodfellow, F. Gao, R. K. Gibb, M. A. Powell, J. S. Rader, and D. G. Mutch Microsatellite Instability and Epigenetic Inactivation of MLH1 and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type J. Clin. Oncol., May 20, 2007; 25(15): 2042 - 2048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Risinger, G. V.R. Chandramouli, G. L. Maxwell, M. Custer, S. Pack, D. Loukinov, O. Aprelikova, T. Litzi, D. S. Schrump, S. K. Murphy, et al. Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression Clin. Cancer Res., March 15, 2007; 13(6): 1713 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Hecht and G. L. Mutter Molecular and Pathologic Aspects of Endometrial Carcinogenesis J. Clin. Oncol., October 10, 2006; 24(29): 4783 - 4791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Black, R. A. Soslow, D. A. Levine, C. Tornos, S. C. Chen, A. J. Hummer, F. Bogomolniy, N. Olvera, R. R. Barakat, and J. Boyd Clinicopathologic Significance of Defective DNA Mismatch Repair in Endometrial Carcinoma J. Clin. Oncol., April 10, 2006; 24(11): 1745 - 1753. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
